GSK: Depemokimab Applications Accepted for Review in China and Japan for Asthma With Type 2 Inflammation and CRSwNP
January 29, 2025
January 29, 2025
LONDON, England, Jan. 29 (TNSjou) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Jan 28, 2025:
* * *
- If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing
- Submissions based on data from positive SWIFT and ANCHOR trials
- SWIFT-1 and -2 showed depemokimab reduced exacerbation and hospitalisation rates as an add-on therapy for patients with asthma with t . . .
* * *
- If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing
- Submissions based on data from positive SWIFT and ANCHOR trials
- SWIFT-1 and -2 showed depemokimab reduced exacerbation and hospitalisation rates as an add-on therapy for patients with asthma with t . . .